Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Sep 2:13:113.
doi: 10.1186/1471-2377-13-113.

Comparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson's disease

Ji Young Yun  1 , Han-Joon Kim, Jee-Young Lee, Young Eun Kim, Ji Seon Kim, Jong-Min Kim, Beom S Jeon
Affiliations
Clinical Trial

Comparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson's disease

Ji Young Yun et al. BMC Neurol. .

Abstract

Background: Ropinirole prolonged release (RPR) is a once-daily formulation. However, there may be individual pharmacokinetic differences so that multiple dosing may be preferred in some individuals. This study compares once-daily and twice-daily RPR in patients with Parkinson's disease.

Methods: This study was an open-label crossover study. We enrolled Parkinson's disease patients on dopamine agonist therapy with unsatisfactory control such as motor fluctuation, dyskinesia and sleep-related problems. Agonists were switched into equivalent dose of RPR. Subjects were consecutively enrolled into either once-daily first or twice-daily first groups, and received the same amount of RPR in a single and two divided dosing for 8 weeks respectively in a crossover manner without a washout period.The primary outcome was a questionnaire of the preference completed by patients in the last visit. The secondary outcome measures included the Unified Parkinson's Disease Rating Scale part 3 (mUPDRS), Hoehn and Yahr stage (H&Y); sleep questionnaire including overall quality of sleep, nocturnal off symptoms and early morning symptoms; Epworth Sleep Scale (ESS); compliances and patient global impression (PGI).

Results: A total of 82 patients were enrolled and 61 completed the study. 31 patients preferred twice-daily regimen, 17 preferred the once-daily regimen, and 13 had no preference. Their mean mUPDRS, H&Y, ESS, sleep quality, compliance and adverse events were not statistically different in both regimens. PGI-improvement on wearing off defined was better in twice-daily dosing regimen.

Conclusions: RPR is a once-daily formulation, but multiple dosing was preferred in many patients. Multiple dosing of RPR might be a therapeutic option if once-daily dosing is unsatisfactory.

Trial registration: ClinicalTrials.gov NCT00986245.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
Subject flow chart.
Figure 3
Figure 3
Patient’s preferences and reasons.
See this image and copyright information in PMC

References

    1. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson’s disease. Neurology. 2000;55(11 Suppl 4):S13–S20. discussion S21-13. - PubMed
    1. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Ease PDMSI. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson’s disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin. 2008;24(10):2883–2895. doi: 10.1185/03007990802387130. - DOI - PubMed
    1. Stocchi F, Giorgi L, Hunter B, Schapira AH. PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease. Mov Disord. 2011;26(7):1259–1265. doi: 10.1002/mds.23498. - DOI - PubMed
    1. Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, Cubo E, Martinez-Martin P, Rascol O, Negre-Pages L. et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord. 2009;24(6):826–832. doi: 10.1002/mds.22112. - DOI - PubMed
    1. Tompson DJ, Vearer D. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson’s disease. Clin Ther. 2007;29(12):2654–2666. doi: 10.1016/j.clinthera.2007.12.010. - DOI - PubMed

Associated data